Q3 FY2026
Filed Nov 17, 2026Auna 3Q26: revenue up 10% FXN with Mexico segment Adjusted EBITDA back to growth, but Adjusted EBITDA fell 5% FXN on Colombia and Peru, and FY26 Adjusted EBITDA outlook was lowered to broadly stable or slightly down
Revenue growth (10% FXN, 19% as reported) and cash generation (YTD free cash flow S/626 million, up 95%) were strong, and leverage improved to 3.5x. Against that, consolidated Adjusted EBITDA was flat as reported and down 5% FXN, Colombia Segment Adjusted EBITDA fell 30% in local currency, net income fell 54% year over year, and the company revised its FY2026 Adjusted EBITDA outlook downward.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Total revenue (3Q26)GAAP | S/1,325 million | 7% as reported (3% FXN) | 19% as reported (10% FXN) |
| Cost of sales and services (3Q26)GAAP | S/(879) million | – | 26% |
| Gross profit (3Q26)GAAP | S/446 million | – | 6% |
| Gross margin (3Q26)GAAP | 33.7% | – | -3.9 p.p. |
| Selling expenses (3Q26)GAAP | S/(62) million | – | 5% |
| Administrative expenses (3Q26)GAAP | S/(232) million | – | 16% |
| Operating profit (3Q26)GAAP | S/158 million | – | -4% |
| Net finance cost (3Q26)GAAP | S/(112) million | 6% | 56% |
| Profit before tax (3Q26)GAAP | S/49 million | -18% | -50% |
| Income tax expense (3Q26)GAAP | S/(24) million | – | -45% |
| Net income (3Q26)GAAP | S/24 million | – | -54% |
| Basic and diluted EPS (3Q26)GAAP | S/0.27 | – | – |
| Adjusted net income (3Q26)non-GAAP | S/35 million | – | – |
| Adjusted basic and diluted EPS (3Q26)non-GAAP | S/0.41 | – | – |
| EBITDA (3Q26)non-GAAP | S/222 million | 0% | -2% |
| Adjusted EBITDA (3Q26)non-GAAP | S/231 million | 2% as reported (stable FXN) | 0% as reported (-5% FXN; -4.6% FXN per highlights) |
| Adjusted EBITDA margin (3Q26)non-GAAP | 17.5% | -0.9 p.p. | -3.3 p.p. |
| Mexico Segment Adjusted EBITDA (3Q26)non-GAAP | S/83 million | 7% as reported (8% LC) | 8% as reported (5% LC) |
| Mexico Segment Adjusted EBITDA margin (3Q26)non-GAAP | 26.3% | 0.4 p.p. | -2.7 p.p. |
| Colombia Segment Adjusted EBITDA (3Q26)non-GAAP | S/43 million | -22% as reported (-30% LC) | -16% as reported (-30% LC) |
| Colombia Segment Adjusted EBITDA margin (3Q26)non-GAAP | 8.8% | -4.3 p.p. | -5.1 p.p. |
| Consolidated Peru Adjusted EBITDA (3Q26)non-GAAP | S/104 million | 3% as reported | -6% as reported |
| Consolidated Peru Adjusted EBITDA margin (3Q26)non-GAAP | 20.2% | 0.4 p.p. | -2.6 p.p. |
| Oncosalud Peru oncology MLR (YTD 26)other | 50.7% | – | 1.4 p.p. |
| Oncosalud Peru overall MLR (YTD 26)other | 58.7% | – | 4.2 p.p. |
| Surgeries (3Q26, Healthcare Network)other | 23,932 | – | 12% |
| Total number of days hospitalized (3Q26, Healthcare Network)other | 144,041 | – | 6% |
| Chemotherapies and radiotherapies (3Q26, Healthcare Network)other | 55,439 | – | 7% |
| Total revenue (YTD 26, nine months)GAAP | S/3,741 million | – | 15% as reported (9% FXN per release table notes not printed; see missing items) |
| Gross margin (YTD 26)GAAP | 35.3% | – | -2.7 p.p. |
| Operating profit (YTD 26)GAAP | S/475 million | – | -1% |
| Net income (YTD 26)GAAP | S/67 million | – | -62% |
| Basic and diluted EPS (YTD 26)GAAP | S/0.76 | – | – |
| Adjusted EBITDA (YTD 26, nine months)non-GAAP | S/676 million | – | -3% |
| Adjusted EBITDA margin (YTD 26)non-GAAP | 18.1% | – | -3.3 p.p. |
| Net cash from operating activities (YTD 26, nine months)GAAP | S/713 million | – | 62% |
| Free Cash Flow (YTD 26, nine months)non-GAAP | S/626 million | – | 95% |
| Net debt (Sep-26)non-GAAP | S/3,133 million | – | -8.6% |
| Leverage ratio (Sep-26)non-GAAP | 3.5x | – | -0.1x |
| Cash and cash equivalents (Sep-26)GAAP | S/614 million | – | 172% |
| Gross debt (Sep-26)non-GAAP | S/3,746 million | – | 3% |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| Healthcare Services MexicoCompany attributes growth to higher surgery and oncology volumes at the Monterrey Healthcare network, partly offset by softer Auna Seguros results. Segment Adjusted EBITDA rose 5% YoY in LC to S/83 million, the first YoY growth in 2026 according to the company. | S/316 million | 6% LC (5% as reported) | 16% LC (20% as reported) |
| Healthcare Services ColombiaCompany cites a 6% rise in protected lives, 7% growth in surgeries, expanded capacity at IMAT Oncomedica in Monteria and growth in PGP arrangements. Segment Adjusted EBITDA fell 30% in LC, which the company links to an adverse oncology risk-sharing contract, regulatory price caps on high-cost oncology medications and higher personnel costs. The risk-sharing contract was terminated after quarter end. | S/494 million | 16% as reported (4% LC) | 34% as reported (12% LC) |
| Healthcare Services PeruCompany cites surgeries up 21%, emergency treatments up 10% and hospitalization days up 6%. Segment Adjusted EBITDA fell 16% YoY to S/37 million, which the company links to a greater focus on high-complexity procedures and higher average revenue per surgery (cost side) in the margin context, and to penalties from the reconciliation of prior years' receivables. | S/307 million | 4% as reported | 10% as reported |
| Oncosalud PeruCompany attributes growth to annual pricing adjustments and 3% growth in plan memberships, and to two new B2B agreements to onboard 4,000 members from 4Q26. Segment Adjusted EBITDA was S/68 million, flat YoY as reported; the company notes higher initial MLR from newly onboarded B2B oncology accounts. | S/323 million | 2% as reported | 10% as reported |
| Consolidated Peru (Healthcare Services Peru and Oncosalud Peru)Company says Peru Adjusted EBITDA was impacted by higher pharmacy costs from new B2B onboarding, higher clinical and nursing payroll, and penalties related to billing matters from the reconciliation of prior years' receivables. The company states that excluding billing-matter impacts, EBITDA growth would have been broadly stable YoY. | S/516 million | 1% as reported | 6% as reported |
| Holding and eliminationsIntersegment revenue elimination. Prior-year comparison shown in the segment table as S/(88) million for 3Q25, with no percentage change printed for this line. | S/(115) million | – | – |
FY2026 outlook
- RevenueFX-neutral revenue growth of 10% to 14% (reaffirmed)
- NoteAdjusted EBITDA: now expected to remain broadly stable or slightly down year-over-year (company states it revised its FY2026 Adjusted EBITDA outlook)
- NoteCapital expenditures: approximately 4% of consolidated revenues (unchanged)
- NoteMedium-term leverage target: below 3.0x (current 3.5x)
Capital returns
- No dividend or share repurchase amounts are reported in the release.
- Company states that it is committed to translating commercial momentum into growing, sustainable returns for shareholders; no specific amount is given.
What drove it
- Company attributes Mexico's return to Segment Adjusted EBITDA growth to the Monterrey Healthcare network, supported by higher surgical and oncology volumes and improved capacity utilization.
- Company attributes the Colombia Segment Adjusted EBITDA decline to an adverse oncology risk-sharing contract, regulatory price caps on high-cost oncology medications and higher personnel costs.
- Company attributes Peru profitability pressure to penalties from reconciliation of prior years' receivables, higher pharmacy and clinical payroll costs, and higher MLR from a larger mix of healthcare plans.
- Company attributes the YoY net income decline mainly to the absence of a S/40 million non-cash FX gain recorded in 3Q25, partly offset by S/20 million lower income tax expense.
- Company attributes the YTD cash flow improvement to working capital management and lower tax payments.
Concerns
- Adjusted EBITDA margin fell to 17.5% from 20.8% in 3Q25 and 18.4% in 2Q26.
- Colombia Segment Adjusted EBITDA down 30% in LC, with margin at 8.8% vs 13.9% in 3Q25.
- Full-year Adjusted EBITDA outlook lowered to broadly stable or slightly down year-over-year.
- Net finance cost rose to S/(112) million from S/(72) million; company attributes the change mainly to the absence of the 3Q25 non-cash FX gain and higher finance costs (including S/6 million non-cash finance expense on the IMAT purchase obligation).
- Net income fell 54% YoY to S/24 million and YTD net income fell 62% to S/67 million.
- Gross margin fell 3.9 p.p. YoY to 33.7%.
- Peru Healthcare Services Segment Adjusted EBITDA fell 16% YoY to S/37 million.
What to watch
- Colombia: outcome of legal review of recovery options under the terminated oncology risk-sharing contract, which the company says represented approximately 4% of Colombia's revenues.
- Mexico: whether Segment Adjusted EBITDA growth continues, given the company's comment on Auna Seguros and VAT deductibility.
- Peru: resolution of billing-matter penalties and the effect of new B2B oncology accounts on MLR.
- Leverage progress toward the medium-term target below 3.0x from 3.5x.
- Centro Ambulatorio Trecca PPP: company expects operations by late 2028.
- Oncology MLR: the release describes the 50.7% figure as both stable and up 1.4 p.p., so the year-over-year direction should be confirmed on the call.
Balance sheet and cash flow
- YTD 26 net cash from operating activities S/713 million vs S/440 million YTD 25 (+62%). Company attributes the S/172 million increase mainly to lower accounts receivable days and better collections in Peru and Mexico, and S/101 million of lower tax payments, primarily from more efficient management of tax returns in Colombia.
- YTD 26 net cash used in investing activities S/(86) million vs S/(119) million YTD 25. Organic maintenance CapEx was S/111 million YTD 26 vs S/113 million YTD 25 per the release.
- YTD 26 net cash used in financing activities S/(363) million vs S/(336) million YTD 25, including S/(228) million of interest and hedge premium payments.
- Gross debt S/3,746 million at Sep-26 vs S/3,656 million at Dec-25 (+2%). Company says the increase was driven mainly by non-cash FX effects (negative S/97 million from PEN depreciation against COP, USD and MXN) and S/46 million of higher accrued interest, partly offset by a S/52 million reduction in short-term debt.
- Total assets S/7,947 million and total equity S/2,119 million at Sep-26 (Dec-25: S/7,298 million and S/1,766 million).
- Cash conversion cycle LTM Sep-26 of -15 days (LTM Jun-26: -10 days; LTM Sep-25: -9 days).
- Loans and borrowings S/3,600 million at Sep-26; Y1 (Oct 2026 to Sep 2027) scheduled repayments S/465 million on loans and borrowings, per the amortization profile.
Analysis
Auna reported 3Q26 consolidated revenue of S/1,325 million, up 19% as reported and 10% FX-neutral, with a company-stated split of 16% LC growth in Mexico, 6% in Peru and 12% in Colombia. Volume indicators were broadly positive: surgeries rose 12% to 23,932, hospitalization days rose 6% and chemotherapy and radiotherapy sessions rose 7%. Gross margin, however, fell to 33.7% from 35.3% on a year-to-date basis and 3.9 p.p. lower YoY in the quarter, and cost of sales grew 26% against 19% revenue growth as reported. Revenue growth was therefore not converted into profit at the same rate.
Profitability was the weak point. Consolidated Adjusted EBITDA was S/231 million, flat as reported and down 5% FXN, with margin at 17.5% against 20.8% in 3Q25. Colombia Segment Adjusted EBITDA fell 30% in LC to S/43 million, and the company links this to an oncology risk-sharing contract, regulatory price caps and higher personnel costs. Consolidated Peru Adjusted EBITDA fell 6% to S/104 million, which the company attributes to new B2B onboarding costs, payroll, and penalties from the reconciliation of prior years' receivables. Mexico was the positive exception: Segment Adjusted EBITDA rose 5% in LC to S/83 million, the first YoY growth in 2026 according to the company.
Below the EBITDA line, net finance cost rose to S/(112) million from S/(72) million. The company says the change mainly reflects the absence of a S/40 million non-cash FX gain in 3Q25 and higher finance costs. Profit before tax fell to S/49 million from S/97 million, and net income fell 54% to S/24 million. GAAP EPS was S/0.27 against S/0.65, and non-GAAP Adjusted EPS was S/0.41 against S/0.71. The gap between these lines is largely the non-cash FX item the company describes.
Cash generation and the balance sheet were stronger. Year-to-date net cash from operating activities rose 62% to S/713 million and free cash flow rose 95% to S/626 million, which the company attributes to working capital and lower tax payments. Net debt fell 8.6% YoY to S/3,133 million, and leverage improved to 3.5x from 3.6x, still above the medium-term target below 3.0x. Gross debt rose 2% from December, which the company attributes mainly to non-cash FX effects and accrued interest. Cash rose to S/614 million from S/226 million a year earlier.
On guidance, the company reaffirmed FY2026 FX-neutral revenue growth of 10% to 14% and capital expenditure of about 4% of revenues. It lowered its Adjusted EBITDA outlook to broadly stable or slightly down year-over-year, citing Colombia and Peru. The Centro Ambulatorio Trecca PPP entered construction on November 3, 2026, with operations currently expected by late 2028. The figures that deserve attention are Colombia margin (8.8%), the Adjusted EBITDA guidance revision, and the GAAP-to-adjusted earnings gap.
Management, verbatim
We have terminated the risk sharing contract to limit further exposure as it represented approximately 4% of Colombia´s revenues and have engaged legal counsel to review all recovery options under the contract.
Suso Zamora, Executive Chairman of the Board and President
We reaffirm our full-year 2026 revenue guidance, expecting FX-neutral growth within our 10% to 14% range. However, reflecting the profitability pressures discussed above, particularly in Colombia, we now expect full-year Adjusted EBITDA to remain broadly stable or slightly down year-over-year.
Suso Zamora, Executive Chairman of the Board and President
Not in the filing
stated, not guessed- Prior-year and prior-quarter figures for consolidated operating profit, income tax, and net income quarter-over-quarter change
- Prior-quarter (2Q26) figures for Mexico, Colombia and Peru segment Adjusted EBITDA margins
- Prior-year consolidated Peru revenue and Adjusted EBITDA in S/ (only percentage changes are printed)
- Prior-year and prior-quarter Adjusted Net Income and Adjusted EPS percentage changes
- Net debt, leverage ratio and cash figures for Jun-26 (prior quarter)
- Prior-year Adjusted EBITDA for YTD 26 by segment for Peru consolidated
- Dividends and share repurchases (none reported in the release)
- Prior guidance document (not provided; vs_prior_guidance left empty)
- Share price reaction and analyst consensus (not in the documents)
- Oncology MLR direction: highlights say stable at 50.7%, body text says up 1.4 p.p.; not reconciled in the filing
- Consolidated YTD revenue FXN growth is not printed; only the as-reported 15% and Mexico/Colombia LC figures appear
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.